Coronary artery bypass surgery hormonal manipulation: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 17: | Line 17: | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Postmenopausalhormonaltherapy([[estrogen]]/[[prosgesterone]])shouldnot be administered to women undergoing CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Postmenopausalhormonaltherapy([[estrogen]]/[[prosgesterone]])shouldnot be administered to women undergoing CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
Revision as of 17:26, 1 November 2016
Coronary artery bypass surgery Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]
Coronary artery bypass surgery hormonal manipulation
| Class I |
| "1. Use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding hypoglycemia is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG (Level of Evidence: B)" |
| Class III: HARM |
| "1. Postmenopausalhormonaltherapy(estrogen/prosgesterone)shouldnot be administered to women undergoing CABG (Level of Evidence: B)" |
| Class IIb |
| "1. The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness (Level of Evidence: B)" |
- ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.